source
- Novo Nordisk's late-stage anti-inflammatory heart drug fails Phase 3 trialNovo Nordisk announced that its experimental anti-inflammatory compound designed to target cardiovascular inflammation did not meet its primary endpoint in a Phase 3 trial. The study was intended…
- ResMed issues correction for Astral ventilators due to electrical component failure riskResMed has released a correction for certain Astral ventilators after identifying a faulty electrical component that could interrupt therapy and cause serious injury or death. The FDA classifies t…